Department of Medicine, Division of Medical Oncology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
J Gastrointest Cancer. 2024 Mar;55(1):153-167. doi: 10.1007/s12029-023-01000-8. Epub 2023 Dec 21.
Cancers of the upper gastrointestinal tract represent a lethal disease entity comprising the esophagus, gastroesophageal junction, and stomach. The backbone of therapy in esophagogastric cancers has predominantly been chemotherapy-based. However, over the last decade, with the debut of immune checkpoint inhibitors, sophisticated molecular testing, and a more comprehensive understanding of the tumor microenvironment, immunotherapy has been incorporated into the treatment of localized and advanced esophagogastric cancers with promising results.
This study aimed to review the unique tumor microenvironment and role of immunotherapy in esophagogastric cancers.
We conducted a systematic review of clinical and translational research for immunotherapy in esophagogastric cancers.
This article will explore the unique tumor microenvironment in gastroesophageal cancers, the role of immunotherapy in localized and advanced disease, challenges in management, and new therapeutic approaches in clinical trials.
With further exploration into targeted therapy and immunotherapy, we anticipate the emergence of novel treatments that will improve survival and quality of life in patients with esophagogastric cancers.
上消化道癌症是一种致命的疾病实体，包括食管、胃食管交界处和胃。食管胃癌症的治疗基础主要是基于化疗。然而，在过去十年中，随着免疫检查点抑制剂、复杂的分子检测以及对肿瘤微环境的更全面理解的出现，免疫疗法已经被纳入局部和晚期食管胃癌症的治疗中，并取得了有希望的结果。
本研究旨在综述食管胃癌症中独特的肿瘤微环境和免疫疗法的作用。
我们对食管胃癌症免疫疗法的临床和转化研究进行了系统综述。
本文将探讨胃食管癌症中独特的肿瘤微环境、免疫疗法在局限性和晚期疾病中的作用、管理中的挑战以及临床试验中的新治疗方法。
随着对靶向治疗和免疫疗法的进一步探索，我们预计将出现新的治疗方法，改善食管胃癌症患者的生存和生活质量。
